| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Mrz―20 |
Persistent rise in device-related errors for CGRP monoclonal antibodies: impact of the COVID-19 pandemic and post-pandemic implications |
Martina Giacon, Salvatore Terrazzino |
| 2 |
[GO] |
2026―Mrz―07 |
Rapid growth and thematic shifts in mRNA therapeutics research catalyzed by the COVID-19 pandemic |
Prabakaran Annadurai |
| 3 |
[GO] |
2025―Jun―06 |
Changes in nationwide thyroid hormone replacement use during the pandemic: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) Study |
Caner Vizdiklar, Volkan Aydin, Onur Gultekin, Gokhan Tazegul, Ahmet Akici |
| 4 |
[GO] |
2025―Mai―06 |
Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis |
Maresa Dulle, Roland Seifert |
| 5 |
[GO] |
2025―Apr―08 |
Outpatient utilization trend of bronchodilator and anti-inflammatory agents in the pandemic and beyond |
N. Ipek Kirmizi Sonmez, Onur Gultekin, Ahmet Akici, Yelda Basbug, Volkan Aydin |
| 6 |
[GO] |
2025―Jan―08 |
Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development |
Sajjad Eslamkhah, Elif Sibel Aslan, Cuneyd Yavas, Nermin Akcalı, Lutfiye Karcıoglu Batur, Asmaa Abuaisha, Erva Esma Yildirim, Mustafa Solak, Kenneth N. White |
| 7 |
[GO] |
2024―Okt―01 |
A critical review on phytochemicals as antiviral medications for SARS-CoV-2 virus infection |
Manoja Das, Namita Panigrahy |
| 8 |
[GO] |
2024―Aug―29 |
Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial |
Zahra Sadat Sanei, Fatemeh Shahrahmani, Behrooz Khaleghi Manesh, Daryoush Hamidi-alamdari, Hassan Mehrad-Majd, Behzad Mavaji Darban, Seyedeh Motahareh Mirdoosti, Mohsen Seddigh-Shamsi |
| 9 |
[GO] |
2024―Jul―20 |
Sotrovimab in the treatment of coronavirus disease-2019 (COVID-19): a systematic review and meta-analysis of randomized clinical trials |
Ana Flávia da Silva Amorim, Joselin Valeska Martinez Sobalvarro, Larissa Helena Torres, Tiago Marques dos Reis |
| 10 |
[GO] |
2024―Mai―14 |
Adverse drug reactions associated with COVID-19 management |
Vivek Chavda, Payal Dodiya, Vasso Apostolopoulos |
| 11 |
[GO] |
2024―Mai―07 |
Thrombocytopenia risks in ARDS COVID-19 patients treated with high-dose linezolid during vvECMO therapy: an observational study |
Pedja Kovacevic, Dragana Milakovic, Tijana Kovacevic, Vedrana Barisic, Sasa Dragic, Biljana Zlojutro, Branislava Miljkovic, Katarina Vucicevic, Zeeshan Rizwan |
| 12 |
[GO] |
2024―Jan―05 |
Remdesivir: treatment of COVID-19 in special populations |
Emad Molaei, Ali Molaei, A. Wallace Hayes, Gholamreza Karimi |
| 13 |
[GO] |
2023―Aug―28 |
Hydroxychloroquine and COVID-19 story: is the low-dose treatment the missing link? A comprehensive review and meta-analysis |
Idir Ramdani, Belaid Bouazza |
| 14 |
[GO] |
2023―Jul―21 |
Perceptions of medicinal herbal products during the COVID-19 pandemic period among Saudi patients: a cross-sectional study |
Aisha Nawaf Al balawi, Alaa R. El-Alosey, Jayda G. Eldiasty, Ismail Y. H. Abushalfeh, Angod Ahmed Almasaude, Sahar Abd-El Razik Mosallam, Alaa Elmetwalli |
| 15 |
[GO] |
2023―Jun―26 |
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020 |
Latifa Aït Moussa, Amina Tebaa, Loubna Alj, Houda Sefiani, Fatima Zahra Meski, Asmae Khattabi, Rachida Soulaymani Bencheikh |
| 16 |
[GO] |
2023―Mrz―26 |
Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary |
Zsófia Gáspár, Bálint Gergely Szabó, Anita Ábrahám, Zsuzsanna Várnai, Noémi Kiss-Dala, János Szlávik, János Sinkó, István Vályi-Nagy, Botond Lakatos |
| 17 |
[GO] |
2023―Feb―11 |
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected |
Francesco Ferrara, Andrea Zovi, Marta Masi, Roberto Langella, Ugo Trama, Mariarosaria Boccellino, Antonio Vitiello |
| 18 |
[GO] |
2023―Jan―12 |
Drug consumption in German cities and municipalities during the COVID-19 lockdown: a wastewater analysis |
Reinhard Oertel, Sara Schubert, Björn Helm, Robin Mayer, Roger Dumke, Ali El-Armouche, Bertold Renner |
| 19 |
[GO] |
2022―Dez―12 |
Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials |
Mohamed Sayed Zaazouee, Mahmoud Eleisawy, Amira M. Abdalalaziz, Mahmoud M. Elhady, Omar Adel Ali, Taghreed Mohamed Abdelbari, Sara Mohamed Hasan, Hossam Waleed Almadhoon, Alaa Yehia Ahmed, Alaa Shaban Fassad, Rewan Elgendy, Eman Adnan Abdel-Baset, Hamis A. Elsayed, Ahmed Bostamy Elsnhory, Alaa Bahaaeldin Abdraboh, Hazem Metwally Faragalla, Alaa Ahmed Elshanbary, Osama A. Kensara, Mohamed M. Abdel-Daim |
| 20 |
[GO] |
2022―Dez―03 |
Cholinergic dysfunction in COVID-19: frantic search and hoping for the best |
Eman Hassan Nadwa, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Engy Elekhnawy, Sarah M. Albogami, Mohammed Alorabi, Gaber El-Saber Batiha, Michel De Waard |
| 21 |
[GO] |
2022―Sep―05 |
Citicoline and COVID-19: vis-à-vis conjectured |
Hayder M. Al-kuraishy, Ali K. Al-Buhadily, Ali I. Al-Gareeb, Mohammed Alorabi, Nasser A. Hadi Al-Harcan, Maisra M. El-Bouseary, Gaber El-Saber Batiha |
| 22 |
[GO] |
2022―Jul―02 |
Pandemic COVID-19, an update of current status and new therapeutic strategies |
Antonio Vitiello, Raffaele La Porta, Ugo Trama, Francesco Ferrara, Andrea Zovi, Amogh Milind Auti, Marina Di Domenico, Mariarosaria Boccellino |
| 23 |
[GO] |
2022―Jun―03 |
Potential effects of icariin, the Epimedium-derived bioactive compound in the treatment of COVID-19: a hypothesis |
Mohammad Rafi Khezri, Fereshteh Nazari-Khanamiri, Tooba Mohammadi, Donya Moloodsouri, Morteza Ghasemnejad-Berenji |
| 24 |
[GO] |
2022―Mrz―18 |
COVID-19 pandemic-related adaptations of medical education in clinical pharmacology - impact on students and lecturers at a German university |
Susanne Hafner, Oliver Zolk, Holger Barth |
| 25 |
[GO] |
2022―Jan―31 |
Vitamin D can reduce severity in COVID-19 through regulation of PD-L1 |
Hatice Aygun |
| 26 |
[GO] |
2022―Jan―28 |
Bradykinin-target therapies in SARS-CoV-2 infection: current evidence and perspectives |
Manuele Figueiredo da Silva, João Xavier de Araújo-Júnior, Edeildo Ferreira da Silva-Júnior, Luana Heimfarth, Paulo Ricardo Martins-Filho, Jullyana de Souza Siqueira Quintans, Lucindo José Quintans-Júnior |
| 27 |
[GO] |
2021―Nov―05 |
Correction to: The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections |
Francesco Ferrara, Antonio Vitiello |
| 28 |
[GO] |
2021―Okt―20 |
Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection |
Antonio Vitiello, Francesco Ferrara |
| 29 |
[GO] |
2021―Okt―20 |
Would carvacrol be a supporting treatment option effective in minimizing the deleterious effects of COVID-19? |
Fernanda Oliveira de Carvalho, Jessica Paloma Rosa Silva, Érika Ramos Silva, Ricardo Luiz Cavalcanti de Albuquerque Júnior, Paula Santos Nunes, Adriano Antunes de Souza Araújo |
| 30 |
[GO] |
2021―Sep―30 |
miRNA-223 as a regulator of inflammation and NLRP3 inflammasome, the main fragments in the puzzle of immunopathogenesis of different inflammatory diseases and COVID-19 |
Sheyda Houshmandfar, Ali Saeedi-Boroujeni, Mohammad Rashno, Ali Khodadadi, Mohammad-Reza Mahmoudian-Sani |
| 31 |
[GO] |
2021―Sep―04 |
Covid-19 and development of heart failure: mystery and truth |
Hope Onohuean, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Safaa Qusti, Eida M. Alshammari, Gaber El-Saber Batiha |
| 32 |
[GO] |
2021―Jun―21 |
The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections |
Francesco Ferrara, Antonio Vitiello |
| 33 |
[GO] |
2021―Mai―07 |
Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19 |
Khadga Raj, Karamjeet Kaur, G. D. Gupta, Shamsher Singh |
| 34 |
[GO] |
2021―Feb―18 |
Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies |
Ailar Nakhlband, Ali Fakhari, Hosein Azizi |
| 35 |
[GO] |
2021―Jan―14 |
Efficacy of synthetic glucocorticoids in COVID-19 endothelites |
Francesco Ferrara, Antonio Vitiello |
| 36 |
[GO] |
2021―Jan―08 |
Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19? |
Mohammad Bahadoram, Bijan Keikhaei, Ali Saeedi-Boroujeni, Mohammad-Reza Mahmoudian-Sani |
| 37 |
[GO] |
2021―Jan―04 |
NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors |
Mahesh Kandasamy |
| 38 |
[GO] |
2020―Sep―06 |
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis |
Yanxiang Zang, Xuejie Han, Meijiao He, Jing Shi, Yue Li |
| 39 |
[GO] |
2020―Mai―27 |
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action |
Emanuele Rizzo |
| 40 |
[GO] |
2020―Mai―25 |
Vitamin D can prevent COVID-19 infection-induced multiple organ damage |
Hatice Aygun |
| 41 |
[GO] |
2020―Mai―19 |
A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19) |
Maryam Rameshrad, Majid Ghafoori, Amir Hooshang Mohammadpour, Mohammad Javad Dehghan Nayeri, Hossein Hosseinzadeh |
| 42 |
[GO] |
2020―Mai―15 |
COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments |
Oliver Zolk, Susanne Hafner, Christoph Q. Schmidt |
